Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
ACET
ACET
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
ACET News
Johnson & Johnson Reports Positive Phase 2b Results for Lupus Drug Nipocalimab, Plans Phase 3 Trial
Jan 06 2026
Benzinga
Adicet Bio Announces 1-for-16 Reverse Stock Split to Maintain Listing Compliance
Dec 26 2025
Benzinga
Adicet Bio (ACET) Approves 1-for-16 Reverse Stock Split to Regain Nasdaq Compliance
Dec 26 2025
NASDAQ.COM
Adicet Bio Implements 1-for-16 Reverse Stock Split to Enhance Nasdaq Compliance
Dec 26 2025
Newsfilter
Adicet Bio Announces 1-for-16 Reverse Stock Split, Reducing Shares to 9.6 Million
Dec 26 2025
Businesswire
Adicet Bio Grants New Employee 20,600 Stock Options at $0.65 Each
Nov 28 2025
Newsfilter
Nutex Health Rises 21% in After-Hours Trading Following Revenue Increase; Biotech Competitors Also See Gains on Tuesday
Nov 19 2025
NASDAQ.COM
Guggenheim Upholds Buy Rating for Adicet Bio (ACET)
Oct 09 2025
NASDAQ.COM
Adicet Bio, Inc. Unveils $80 Million Registered Direct Offering
Oct 07 2025
Newsfilter
Adicet Bio Reports Encouraging Initial Results from Phase 1 Trial of ADI-001 in Lupus Nephritis and Systemic Lupus Erythematosus Patients
Oct 07 2025
Newsfilter
Guggenheim Affirms Buy Rating for Adicet Bio, Keeps $7 Price Target Intact
Sep 19 2025
Benzinga
Adicet Bio Announces Inducement Grants in Compliance with Nasdaq Listing Rule 5635(c)(4)
Aug 29 2025
Newsfilter
Adicet Bio (ACET) Upgraded to Buy: Here's Why
Aug 12 2025
NASDAQ.COM
Adicet Bio to Participate in a Fireside Chat at the 45th Annual Canaccord Genuity Growth Conference
Aug 05 2025
Newsfilter
HC Wainwright & Co. Assumes Adicet Bio at Buy, Announces Price Target of $4
Jul 23 2025
Benzinga
Why Block Shares Are Trading Higher By 10%; Here Are 20 Stocks Moving Premarket
Jul 21 2025
Benzinga
Show More News
